<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958864</url>
  </required_header>
  <id_info>
    <org_study_id>CC-90001-CP-006</org_study_id>
    <secondary_id>U1111-1229-5813</secondary_id>
    <nct_id>NCT03958864</nct_id>
  </id_info>
  <brief_title>A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects</brief_title>
  <official_title>A PHASE 1, OPEN LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY/TOLERABILITY OF CC-90001 IN JAPANESE HEALTHY SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, randomized, parallel design study to evaluate the PK and
      safety/tolerability of CC 90001 in Japanese and Caucasian healthy adult subjects.

      The study will consist of multiple oral doses of IP (QD x 7 days) in 3 planned dose level
      cohorts of 100 mg, 200 mg, and 400 mg. Each cohort will have 20 subjects (10 Japanese
      subjects and 10 Caucasian subjects, with a minimum of 8 subjects to complete in each group)
      who will receive IP (see below).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">June 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic- AUC0-t</measure>
    <time_frame>Day 1 and Day 7- 10</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to the time point of the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- AUC0-âˆž</measure>
    <time_frame>Day 1 and Day 7- 10</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- CL/F</measure>
    <time_frame>Day 1 and Day 7- 10</time_frame>
    <description>Estimation of apparent clearance of drug from plasma after extravascular administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Vz/F</measure>
    <time_frame>Day 1 and Day 7- 10</time_frame>
    <description>Estimation of apparent volume of distribution during the terminal phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Cmax</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Estimation of observed maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Tmax</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Estimation of time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- t1/2</measure>
    <time_frame>Day 1 and Day 7- 10</time_frame>
    <description>Description: Estimation of terminal elimination half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From enrollment until at least 28 days after completion of study treatment</time_frame>
    <description>Number participants with Adverse Event</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>CC-90001 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of CC-90001 (once daily [QD] x 7 days) will be given orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of CC-90001 (once daily [QD] x 7 days) will be given orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of CC-90001 (once daily [QD] x 7 days) will be given orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001</description>
    <arm_group_label>CC-90001 100 mg</arm_group_label>
    <arm_group_label>CC-90001 200 mg</arm_group_label>
    <arm_group_label>CC-90001 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must satisfy all of the following criteria to be enrolled in the study:

          1. Healthy, adult, male and female subjects.

          2. Japanese subjects who were born in Japan and not have lived outside of Japan for more
             than 10 years, have both parents and grandparents of Japanese origin, and have not
             significantly modified their diets since leaving Japan.

          3. Caucasian subjects who have age and body mass index matched with Japanese subjects.

        Exclusion Criteria:

          1. Has any significant medical condition, laboratory abnormality, or psychiatric illness
             that would prevent the subject from participating in the study or place the subject at
             unacceptable risk if he/she were to participate in the study.

          2. Use of any prescribed systemic or topical medication within 30 days of the first dose
             administration.

          3. Has any surgical or medical condition(s) possibly affecting drug absorption,
             distribution, metabolism, and excretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Ye, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paraxel International</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <keyword>CC-90001</keyword>
  <keyword>Japanese</keyword>
  <keyword>Caucasian</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

